Compare TXT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXT | SNY |
|---|---|---|
| Founded | 1923 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | TXT | SNY |
|---|---|---|
| Price | $90.87 | $48.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $92.33 | $61.50 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 01-21-2026 | 01-29-2026 |
| Dividend Yield | 0.09% | ★ 3.31% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 4.55 | ★ 8.67 |
| Revenue | $14,237,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $8.63 | $1.73 |
| Revenue Next Year | $4.98 | $6.49 |
| P/E Ratio | $19.91 | ★ $5.57 |
| Revenue Growth | ★ 1.83 | N/A |
| 52 Week Low | $57.70 | $44.62 |
| 52 Week High | $91.22 | $60.12 |
| Indicator | TXT | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 73.20 | 45.38 |
| Support Level | $85.62 | $47.70 |
| Resistance Level | $91.22 | $48.74 |
| Average True Range (ATR) | 1.60 | 0.64 |
| MACD | 0.52 | 0.01 |
| Stochastic Oscillator | 96.11 | 50.36 |
Textron is a conglomerate that designs, manufactures, and services a range of specialty aircraft including small jets, propeller-driven airplanes, helicopters, and tilt-rotor aircraft. Textron Aviation manufactures and services Cessna and Beechcraft planes. Bell is a helicopter and tilt-rotor manufacturer and servicer for both commercial and military customers. Textron Systems produces uncrewed aircraft and armored vehicles for the military market as well as aircraft simulators and training for the commercial and military markets. Textron Industrial contains the Kautex business, which manufactures plastic fuel tanks for conventional and hybrid motor vehicles, and other subsidiaries that produce specialized vehicles such as golf carts and all-terrain vehicles.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.